Optiver Holding’s Castle Biosciences CSTL Stock Holding History

Optiver Holding’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-40	Closed	-$911	–	2586
2025 Q3	$911	Buy	+40	New	+$813	﹤0.01%	2508

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Optiver Holding's CSTL Position: Q4 2025 in Review

Optiver Holding sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 40 shares — an estimated $911 sold.

Optiver Holding first reported a position in CSTL in Q3 2025 and held it in 1 quarter. The position peaked at $911 in Q3 2025. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

Optiver Holding reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 40 Castle Biosciences shares in Q4 2025, an estimated $911.
Optiver Holding first reported a position in Castle Biosciences in Q3 2025 and held it in 1 quarter.
Optiver Holding's Castle Biosciences position peaked at $911 in Q3 2025.
194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.